LONDON, March 26, 2015 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Investor-Edge.com has issued free post-earnings analysis on Allscripts Healthcare Solutions Inc. (NASDAQ: MDRX). On February 26, 2015, the company reported its financial results for Q4 FY14 and full year FY14 (period ended December 31, 2014). Click on http://get.Investor-Edge.com/pdf/?c=Allscripts%20Healthcare%20Solutions&d=26-Mar-2015&s=MDRX to read our free earnings review on Allscripts Healthcare Solutions Inc. (Allscripts). During Q4 FY14 and full-year FY14, the company reported total GAAP revenue of $340.9 million and $1.38 billion, respectively. Further, Allscripts' adjusted EBITDA improved 8% Y-o-Y in Q4 FY14 and 11% Y-o-Y in FY14. Our free coverage report can be accessed at:

http://get.Investor-Edge.com/pdf/?c=Allscripts%20Healthcare%20Solutions&d=26-Mar-2015&s=MDRX

Earnings Overview

During Q4 FY14, Allscripts' total GAAP revenue fell 3% Y-o-Y from $351.0 million in Q4 FY13. The company's Q4 FY14 total GAAP revenue missed Bloomberg analysts' forecast of $357.4 million. Allscripts' total non- GAAP revenue came in at $343.2 million in Q4 FY14 compared to $353.6 million in Q4 FY13. Additionally, bookings in Q4 FY14 were down 11% to $244 million from $274 million in Q4 FY13. Free research on MDRX can be downloaded in PDF format at:

http://get.Investor-Edge.com/pdf/?c=Allscripts%20Healthcare%20Solutions&d=26-Mar-2015&s=MDRX

During Q4 FY14, Allscripts' GAAP gross margin was 40.0% compared with 39.4% in Q4 FY13. The company's adjusted EBITDA stood at $52.3 million for Q4 FY14 compared with $48.5 million in Q4 FY13.

In Q4 FY14, Allscripts reported GAAP net loss of $2.2 million, or $0.01 loss per diluted share, compared to GAAP net loss of $20.6 million, or $0.12 loss per diluted share, in Q4 FY13. Bloomberg analysts had expected GAAP net loss of $7.9 million, or $0.06 loss per diluted share, in Q4 FY14. However, Allscripts' Q4 FY14 non-GAAP net income improved to $16.9 million or $0.09 per diluted share from $14.0 million, or $0.08 per diluted share in Q4 FY13.

President and CEO of Allscripts, Paul M. Black, stated that the company's Q4 FY14 non-GAAP EPS increased despite a lack of revenue growth in the quarter. He informed that the company also generated strong operating cash flow in the Q4 FY14, which drove a significant improvement in free cash flow for FY14 compared with FY13. The investments the company made to improve its solutions are driving higher client satisfaction and positioning Allscripts for long-term growth, he added.

For FY14, Allscripts' total GAAP revenue improved $4.8 million Y-o-Y from $1.37 billion in FY13. The company's FY14 total GAAP revenue missed Bloomberg analysts' forecast of $1.40 billion. Allscripts' total non-GAAP revenue was $1.39 billion in FY14 compared to $1.38 billion in FY13. Furthermore, bookings during FY14 improved 2% Y-o-Y to $923 million. Sign up and read the free analyst's notes on MDRX at:

http://get.Investor-Edge.com/pdf/?c=Allscripts%20Healthcare%20Solutions&d=26-Mar-2015&s=MDRX

During FY14, the company's adjusted EBITDA stood at $199.0 million compared to $179.8 million in FY13. Allscripts reported GAAP net loss of $66.5 million, or $0.37 loss per diluted share, in FY14 compared to GAAP net loss of $104.0 million, or $0.59 loss per diluted share, in FY13. Bloomberg analysts had expected GAAP net loss of $70.3 million, or $0.36 loss per diluted share, in FY14. The company's non-GAAP net income increased to $56.3 million, or $0.31 per diluted share, in FY14 from $48.2 million, or $0.27 per diluted share, in FY13.

Mr. Black said the company is optimistic about the sustainability of several business trends creating a foundation of stability and a trajectory for growth and continued innovation. He further stated that the company achieved a healthy mix of add-on sales across Allscripts clients in FY14, reflecting the nearly half a billion dollars the company has spent on research and development over the last two years.

In its FY15 financial guidance, Allscripts expects revenue to be between $1.43 billion and $1.46 billion with adjusted EBITDA in the range of $230 million to $250 million. The company also anticipates FY15 non-GAAP diluted EPS to be between $0.42 and $0.50. Visit Investor-Edge and access the latest research on MDRX at:

http://get.Investor-Edge.com/pdf/?c=Allscripts%20Healthcare%20Solutions&d=26-Mar-2015&s=MDRX

Stock Performance

On the day following the earnings release, February 27, 2015, Allscripts' stock plummeted 5.84% to end the session at $12.01. Since then, the stock has moved both ways. On the last close, Wednesday, March 25, 2015, the company's shares finished 3.57% lower at $11.89, after vacillating between $11.89 and $12.32. A total of 1.52 million shares were traded which was below their three months average volume of 3.41 million shares. The stock has fallen by 1.33% in previous three trading sessions. Further, over the last one month and over the past three months, the company's shares have lost 6.93% and 7.61%, respectively.

Sneak Peek to Corporate Insider Trading

In the last one month, there were 13 corporate insider transactions done by five individuals. On March 06, 2015, a total of 29,081 shares have been disposed at an average price of $12.17 per share and for a total value of $353,916. The following are some transactions during the aforementioned day: Paul M. Black, sold 14,809 shares at an average price of $12.17 per share; Richard (Rick) J. Poulton, Chief Financial Officer at Allscripts, and Dennis Olis, Senior Vice President, Operations at Allscripts, disposed 5,950 and 3,798 shares, respectively, at an average price of $12.17 per share. Complimentary in-depth research on MDRX is available at:

http://get.Investor-Edge.com/pdf/?c=Allscripts%20Healthcare%20Solutions&d=26-Mar-2015&s=MDRX

About Investor-Edge.com

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.

SOURCE Investor-Edge